Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2024

Open Access 01-12-2024 | Computed Tomography | Research

Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial

Authors: Lingzhou Zhao, Yan Xing, Changcun Liu, Shaofei Ma, Wenhua Huang, Zhen Cheng, Jinhua Zhao

Published in: Breast Cancer Research | Issue 1/2024

Login to get access

Abstract

Background

99mTc radiolabeled nanobody NM-02 (99mTc-NM-02) is a novel single photon emission computed tomography (SPECT) probe with a high affinity and specificity for human epidermal growth factor receptor 2 (HER2). In this study, a clinical imaging trial was conducted to investigate the relationship between 99mTc-NM-02 uptake and HER2 expression in patients with breast cancer.

Methods

Thirty patients with pathologically confirmed breast cancer were recruited and imaged with both 99mTc-NM-02 SPECT/computed tomography (CT) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT. According to the treatment conditions before recruitment, patients were divided into two groups, the newly diagnosed group (n = 24) and the treated group (n = 6). The maximal standard uptake value (SUVmax) of 18F-FDG and SUVmax and mean SUV (SUVmean) of 99mTc-NM-02 in the lesions were determined to analyze the relationship with HER2 expression.

Results

No meaningful relationship was observed between 18F-FDG uptake and HER2 expression in 30 patients with breast cancer. 99mTc-NM-02 uptake was positively correlated with HER2 expression in the newly diagnosed group, but no correlation was observed in the treated group. 99mTc-NM-02 uptake in HER2-positive lesions was lower in those with effective HER2-targeted therapy compared with the newly diagnosed group. 99mTc-NM-02 SPECT/CT detected brain and bone metastases of breast cancer with a different imaging pattern from 18F-FDG PET/CT. 99mTc-NM-02 showed no non-specific uptake in inflamed tissues and revealed intra- and intertumoral HER2 heterogeneity by SPECT/CT imaging in 9 of the 30 patients with breast cancer.

Conclusions

99mTc-NM-02 SPECT/CT has the potential for visualizing whole-body HER2 overexpression in untreated patients, making it a promising method for HER2 assessment in patients with breast cancer.

Trial registration

NCT04674722, Date of registration: December 19, 2020.
Appendix
Available only for authorised users
Literature
1.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2019;382:597–609.CrossRefPubMed
2.
Biabani Ardakani J, Akhlaghi M, Nikkholgh B, Hosseinimehr SJ. Targeting and imaging of HER2 overexpression tumor with a new peptide-based 68Ga-PET radiotracer. Bioorg Chem. 2021;106:104474.CrossRefPubMed
3.
4.
Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17:233–50.CrossRefPubMed
5.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105–22.CrossRefPubMed
6.
Pfitzner BM, Lederer B, Lindner J, Solbach C, Engels K, Rezai M, et al. Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years. Mod Pathol. 2018;31:607–15.CrossRefPubMed
7.
Hamilton E, Shastry M, Shiller SM, Ren R. Targeting HER2 heterogeneity in breast cancer. Cancer Treat Rev. 2021;100:102286.CrossRefPubMed
8.
Gebhart G, Flamen P, De Vries EGE, Jhaveri K, Wimana Z. Imaging diagnostic and therapeutic targets: human epidermal growth factor receptor 2. J Nucl Med. 2016;57:S81–8.CrossRef
9.
Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27:619–24.CrossRefPubMed
10.
11.
Tolmachev V, Orlova A, Sörensen J. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer. Semin Cancer Biol. 2021;72:185–97.CrossRefPubMed
12.
Altunay B, Morgenroth A, Beheshti M, Vogg A, Wong NCL, Ting HH, et al. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur J Nucl Med Mol Imaging. 2021;48:1371–89.CrossRefPubMed
13.
14.
Wu Y, Li L, Wang Z, Shi J, Hu Z, Gao S, et al. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99mTc-HYNIC-H10F. Eur J Nucl Med Mol Imaging. 2020;47:2613–23.CrossRefPubMed
15.
16.
Chakravarty R, Goel S, Cai W. Nanobody: the magic bullet. Mol Imaging? Theranostics. 2014;4:386–98.CrossRef
17.
Salvador JP, Vilaplana L, Marco MP. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. 2019;411:1703–13.CrossRefPubMed
18.
Vaidyanathan G, McDougald D, Choi J, Koumarianou E, Weitzel D, Osada T, et al. Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET. J Nucl Med. 2016;57:967–73.CrossRefPubMed
19.
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, et al. Preclinical targeted α- and β–-radionuclide therapy in HER2-positive brain metastasis using camelid single-domain antibodies. Cancers. 2020;12:1017.CrossRefPubMedPubMedCentral
20.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27–33.CrossRefPubMed
21.
D’Huyvetter M, De Vos J, Xavier C, Pruszynski M, Sterckx YGJ, Massa S, et al. 131I-labeled anti-HER2 camelid sdAb as a theranostic tool in cancer treatment. Clin Cancer Res. 2017;23:6616–28.CrossRefPubMedPubMedCentral
22.
D’Huyvetter M, Vos JD, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, et al. Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med. 2021;62:1097–105.CrossRefPubMed
23.
Zhao L, Liu C, Xing Y, He J, O’Doherty J, Huang W, et al. Development of a 99mTc-labeled single-domain antibody for SPECT/CT assessment of HER2 expression in breast cancer. Mol Pharm. 2021;18:3616–22.CrossRefPubMed
24.
Qiao W, Zhao J, Wang C, Wang T, Xing Y. Predictive value of 18F-FDG hybrid PET/CT for the clinical outcome in patients with Non-hodgkin’s lymphoma prior to and after autologous stem cell transplantation. Hematology. 2010;15:21–7.CrossRefPubMed
25.
Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54:34–44.CrossRefPubMed
26.
Bragina O, von Witting E, Garousi J, Zelchan R, Sandström M, Orlova A, et al. Phase I study of 99mTc-ADAPT6, a Scaffold protein-based probe for visualization of HER2 expression in breast Cancer. J Nucl Med. 2021;62:493–9.CrossRefPubMedPubMedCentral
27.
Oroujeni M, Rinne SS, Vorobyeva A, Loftenius A, Feldwisch J, Jonasson P, et al. Preclinical evaluation of 99mTc-ZHER2:41071, a second-generation affibody-based HER2-Visualizing imaging probe with a low renal uptake. Int J Mol Sci. 2021;22:2770.CrossRefPubMedPubMedCentral
28.
Bragina O, Chernov V, Schulga A, Konovalova E, Garbukov E, Vorobyeva A, et al. Phase I trial of 99mTc-(HE)3-G3, a DARPin-Based probe for imaging of HER2 expression in breast Cancer. J Nucl Med. 2022;63:528–35.CrossRefPubMedPubMedCentral
29.
Li L, Liu T, Shi L, Zhang X, Guo X, Hu B, et al. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking. Theranostics. 2022;12:5551–63.CrossRefPubMedPubMedCentral
30.
Shi J, Du S, Wang R, Gao H, Luo Q, Hou G, et al. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study. J Transl Med. 2023;21:19.CrossRefPubMedPubMedCentral
31.
Qin X, Guo X, Liu T, Li L, Zhou N, Ma X, et al. High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers. Eur J Nucl Med Mol Imaging. 2023;50:302–13.CrossRefPubMed
32.
Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET/CT. Theranostics. 2016;6:262–71.CrossRefPubMedPubMedCentral
33.
Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21755 patients from the Japanese breast cancer registry. Ann Oncol. 2016;27:480–7.CrossRefPubMed
34.
Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat. 2019;175:401–8.CrossRefPubMed
Metadata
Title
Detection of HER2 expression using 99mTc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial
Authors
Lingzhou Zhao
Yan Xing
Changcun Liu
Shaofei Ma
Wenhua Huang
Zhen Cheng
Jinhua Zhao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2024
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-024-01803-y

Other articles of this Issue 1/2024

Breast Cancer Research 1/2024 Go to the issue

Research

Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates

Research

Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover

Research

EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis

Research

Deep learning of mammogram images to reduce unnecessary breast biopsies: a preliminary study

Research

Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients

Research

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits